GenSight Biologics S.A. (EPA:SIGHT)
France · Delayed Price · Currency is EUR 0.1148
+0.0096 (9.13%)
Aug 21, 2026, 5:35 PM CET
GenSight Biologics Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2.42 | 2.46 | 2.13 | 10.61 | 44.29 |
Cash & Short-Term Investments | 2.42 | 2.46 | 2.13 | 10.61 | 44.29 |
Cash Growth | -1.99% | 15.46% | -79.89% | -76.04% | 16.72% |
Accounts Receivable | - | 0 | 0 | - | 0.75 |
Other Receivables | 1.58 | 1.99 | 2.4 | 3.49 | 3.54 |
Receivables | 1.58 | 1.99 | 2.4 | 3.49 | 4.3 |
Prepaid Expenses | 0.15 | 0.28 | 1.63 | 8.21 | 2.55 |
Other Current Assets | 0.84 | 0.61 | 0.37 | 0.63 | 2.23 |
Total Current Assets | 4.98 | 5.34 | 6.53 | 22.95 | 53.36 |
Property, Plant & Equipment | 0.43 | 0.93 | 2.03 | 2.27 | 2.55 |
Other Intangible Assets | - | 0.06 | 0.08 | 0.09 | 0.11 |
Other Long-Term Assets | 2.85 | 4.42 | 0.5 | 0.63 | 0.62 |
Total Assets | 8.26 | 10.76 | 9.13 | 25.94 | 56.65 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.92 | 6.36 | 5.63 | 7.81 | 11.56 |
Accrued Expenses | 2.14 | 1.73 | 1.79 | 3.61 | 2.45 |
Current Portion of Long-Term Debt | 3.3 | 13.31 | 16.61 | 1.54 | 4.68 |
Current Portion of Leases | 0.35 | 0.59 | 0.78 | 0.89 | 0.74 |
Current Income Taxes Payable | 0.25 | 0.17 | 0.03 | 0.03 | 0.02 |
Current Unearned Revenue | - | - | 0.07 | 0.03 | 0.2 |
Other Current Liabilities | 0.72 | 0.46 | 0.4 | 0.73 | 2.6 |
Total Current Liabilities | 12.67 | 22.62 | 25.29 | 14.64 | 22.24 |
Long-Term Debt | 9.22 | - | 5.11 | 14.46 | 10.58 |
Long-Term Leases | 0 | 0.51 | 1.05 | 0.97 | 1.51 |
Long-Term Unearned Revenue | - | - | - | 0.19 | 0.42 |
Pension & Post-Retirement Benefits | 1.1 | 1.17 | 1.26 | 0.02 | 0.04 |
Other Long-Term Liabilities | 10.2 | 13.38 | 7.13 | 10.93 | 5.86 |
Total Liabilities | 33.2 | 37.68 | 39.83 | 41.22 | 40.66 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 5.52 | 3.12 | 1.63 | 1.16 | 1.16 |
Additional Paid-In Capital | 217.41 | 206.61 | 190.94 | 181.21 | 181.18 |
Retained Earnings | -12.04 | -14 | -26.22 | -27.63 | -28.62 |
Comprehensive Income & Other | -235.83 | -222.64 | -197.05 | -170.02 | -137.73 |
Shareholders' Equity | -24.94 | -26.92 | -30.7 | -15.28 | 15.99 |
Total Liabilities & Equity | 8.26 | 10.76 | 9.13 | 25.94 | 56.65 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 12.86 | 14.41 | 23.54 | 17.86 | 17.51 |
Net Cash (Debt) | -10.45 | -11.95 | -21.4 | -7.25 | 26.78 |
Net Cash Growth | - | - | - | - | 42.36% |
Net Cash Per Share | -0.07 | -0.12 | -0.44 | -0.16 | 0.59 |
Filing Date Shares Outstanding | 220.32 | 128.15 | 64.97 | 46.18 | 46.24 |
Total Common Shares Outstanding | 220.32 | 128.15 | 64.97 | 46.18 | 46.24 |
Working Capital | -7.69 | -17.28 | -18.76 | 8.31 | 31.12 |
Book Value Per Share | -0.11 | -0.21 | -0.47 | -0.33 | 0.35 |
Tangible Book Value | -24.94 | -26.98 | -30.78 | -15.37 | 15.88 |
Tangible Book Value Per Share | -0.11 | -0.21 | -0.47 | -0.33 | 0.34 |
Machinery | 1.23 | 1.23 | 1.23 | 1.22 | 1.36 |
Leasehold Improvements | 1.31 | 1.38 | 1.35 | 1.37 | 0.98 |